Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.

Crawford A, Haber L, Kelly MP, Vazzana K, Canova L, Ram P, Pawashe A, Finney J, Jalal S, Chiu D, Colleton CA, Garnova E, Makonnen S, Hickey C, Krueger P, DelFino F, Potocky T, Kuhnert J, Godin S, Retter MW, Duramad P, MacDonald D, Olson WC, Fairhurst J, Huang T, Martin J, Lin JC, Smith E, Thurston G, Kirshner JR.

Sci Transl Med. 2019 Jun 19;11(497). pii: eaau7534. doi: 10.1126/scitranslmed.aau7534.

PMID:
31217340
2.

ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts.

Cheal SM, Ruan S, Veach DR, Longo VA, Punzalan BJ, Wu J, Fung EK, Kelly MP, Kirshner JR, Giurleo JT, Ehrlich G, Han AQ, Thurston G, Olson WC, Zanzonico PB, Larson SM, Carrasquillo JA.

Mol Pharm. 2018 Jun 4;15(6):2133-2141. doi: 10.1021/acs.molpharmaceut.7b01133. Epub 2018 Apr 30.

3.

Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids.

Nittoli T, Kelly MP, Delfino F, Rudge J, Kunz A, Markotan T, Spink J, Chen Z, Shan J, Navarro E, Tait M, Provoncha K, Giurleo J, Zhao F, Jiang X, Hylton D, Makonnen S, Hickey C, Kirshner JR, Thurston G, Papadopoulos N.

Bioorg Med Chem. 2018 May 15;26(9):2271-2279. doi: 10.1016/j.bmc.2018.02.025. Epub 2018 Feb 21.

PMID:
29605304
4.

Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody-Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers.

Kelly MP, Hickey C, Makonnen S, Coetzee S, Jalal S, Wang Y, Delfino F, Shan J, Potocky TB, Chatterjee I, Andreev J, Kunz A, D'Souza C, Giurleo JT, Nittoli T, Trail PA, Thurston G, Kirshner JR.

Mol Cancer Ther. 2017 Jul;16(7):1299-1311. doi: 10.1158/1535-7163.MCT-16-0839. Epub 2017 Apr 4.

5.

Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs.

Andreev J, Thambi N, Perez Bay AE, Delfino F, Martin J, Kelly MP, Kirshner JR, Rafique A, Kunz A, Nittoli T, MacDonald D, Daly C, Olson W, Thurston G.

Mol Cancer Ther. 2017 Apr;16(4):681-693. doi: 10.1158/1535-7163.MCT-16-0658. Epub 2017 Jan 20.

6.

In-silico discovery of cancer-specific peptide-HLA complexes for targeted therapy.

Dhanik A, Kirshner JR, MacDonald D, Thurston G, Lin HC, Murphy AJ, Zhang W.

BMC Bioinformatics. 2016 Jul 20;17:286. doi: 10.1186/s12859-016-1150-2.

7.

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.

Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD, Oyejide A, Kirshner JR, Canova L, Menon J, Principio J, MacDonald D, Kantrowitz J, Papadopoulos N, Stahl N, Yancopoulos GD, Thurston G, Davis S.

Sci Rep. 2015 Dec 11;5:17943. doi: 10.1038/srep17943.

8.

Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.

Kuhnert F, Chen G, Coetzee S, Thambi N, Hickey C, Shan J, Kovalenko P, Noguera-Troise I, Smith E, Fairhurst J, Andreev J, Kirshner JR, Papadopoulos N, Thurston G.

Cancer Res. 2015 Oct 1;75(19):4086-96. doi: 10.1158/0008-5472.CAN-14-3773. Epub 2015 Sep 16.

9.

Dll4-Notch signaling as a therapeutic target in tumor angiogenesis.

Kuhnert F, Kirshner JR, Thurston G.

Vasc Cell. 2011 Sep 18;3(1):20. doi: 10.1186/2045-824X-3-20.

10.

Ongoing Dll4-Notch signaling is required for T-cell homeostasis in the adult thymus.

Billiard F, Kirshner JR, Tait M, Danave A, Taheri S, Zhang W, Waite JC, Olson K, Chen G, Coetzee S, Hylton D, Murphy AJ, Yancopoulos GD, Thurston G, Skokos D.

Eur J Immunol. 2011 Aug;41(8):2207-16. doi: 10.1002/eji.201041343. Epub 2011 Jul 4.

11.

Elesclomol induces cancer cell apoptosis through oxidative stress.

Kirshner JR, He S, Balasubramanyam V, Kepros J, Yang CY, Zhang M, Du Z, Barsoum J, Bertin J.

Mol Cancer Ther. 2008 Aug;7(8):2319-27. doi: 10.1158/1535-7163.MCT-08-0298.

12.

Identification of TRAIL as an interferon regulatory factor 3 transcriptional target.

Kirshner JR, Karpova AY, Kops M, Howley PM.

J Virol. 2005 Jul;79(14):9320-4.

13.
18.

Supplemental Content

Loading ...
Support Center